

REMARKS

Claims 569-717, 719-869, 871-1021, 1023-1173, 1175-1294, 1296-1407, 1409-1568, 1570-1612 and 1614-1727 were previously pending in this application. Claims 594, 719, 746, 871, 898, 1023, 1050, 1175, 1202, 1297, 1321, 1409, 1470-1471, 1480, 1570, 1572, 1602, 1611, 1689, 1698-1699, 1707 and 1718 have been amended above by underlining the added subject matter and deleting the bracketed subject matter. Accordingly, claims 569-717, 719-869, 871-1021, 1023-1173, 1175-1294, 1296-1407, 1409-1568, 1570-1612 and 1614-1727 are presented for further examination.

This paper follows today's telephone conversation with Ms. Tina Plunkett, Program Analyst, Group Art Unit 1631, U.S. Patent and Trademark Office. During that conversation, reference was made to Applicants' August 31, 2000 Second Supplemental Amendment and the amendments to twenty-four (24) claims which were made as "wholly rewritten" forms. Those wholly rewritten claims included claims 594, 719, 746, 871, 898, 1023, 1050, 1175, 1202, 1297, 1321, 1409, 1470-1471, 1480, 1570, 1572, 1602, 1611, 1689, 1698-1699, 1707 and 1718. It was decided that those amended 24 claims should be submitted as amended claims using conventional underlining and bracketing. Thus, with the implementation of the underlining and bracketing, the amended claims above correspond to the wholly rewritten forms presented in Applicants' August 31, 2000 Second Supplemental Amendment.

Entry of the above amendments is respectfully requested.

* * * * *

Dean L. Engelhardt, et al.
Serial No.: 08/486,069
Filed: June 7, 1995
Page 10 [Third Supplemental Amendment (Following Applicants'
September 8, 2000 Communication) - November 16, 2000]

SUMMARY AND CONCLUSIONS

Claims 569-717, 719-869, 871-1021, 1023-1173, 1175-1294, 1296-1407, 1409-1568, 1570-1612 and 1614-1727 are presented for further examination in this application. Of these claims, claims 594, 719, 746, 871, 898, 1023, 1050, 1175, 1202, 1297, 1321, 1409, 1470-1471, 1480, 1570, 1572, 1602, 1611, 1689, 1699, 1707 and 1718 have been amended by inserting underlined subject matter and deleting bracketed subject matter.

No fee or fees are believed due in connection with the above amendments to the claims, no additional claims having been presented. In the event that any fee or fees are due, however, authorization is hereby given to charge the amount of any such fee(s) to Deposit Account No. 05-1135, or to credit any overpayment thereto.

If a telephone conversation would further the prosecution of the present application, Applicants' undersigned attorney request that he be contacted at the number provided below.

Respectfully submitted,



Ronald C. Fedus
Registration No. 32,567
Attorney for Applicants

ENZO DIAGNOSTICS, INC.
c/o ENZO BIOCHEM, INC.
527 Madison Avenue, 9th Floor
New York, New York 10022
Telephone: (212) 583-0100
Facsimile: (212) 583-0150